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The alpha interferons have recently undergone extensive
phase I and II investigation in numerous tumour sites. The
antineoplastic activity of various alpha interferon prepara-
tions in renal cell carcinoma has been documented by several
investigators (Quesada et al., 1983, 1985; Neidhart et al.,
1984; Kirkwood et al., 1985). In all of these studies the
interferon was administered as a daily or three times weekly
intramuscular injection.
Recently, Connors and Silver (1984) reported the results of
a phase I trial in which human lymphoblastoid interferon
was given in a novel weekly i.v. bolus schedule. Doses were
escalated according to patient tolerance. No myelo-
suppression or hepatic dysfunction was detected. The
primary toxicities were chills, fever, myalgia and fatigue.
Following the completion of this phase I study, the
National Cancer Institute of Canada Clinical Trials Group
initiated a phase II study of interferon given in this schedule
in patients with advanced renal cell carcinoma. The results of
this study are the subject of this report.
Patients with histologically documented measurable
advanced renal cell carcinoma were entered into the study.
Patients were eligible if they had an ECOG (Eastern
Cooperative Oncology Group) performance status of 0, 1 or
2; absolute granulocyte count > 1,500mm-, platelet count
> 125,000mm 3, serum creatinine <2504umol 1 1, liver
enzymes no greater than twice the upper limit of normal, no
major cardiac disease and no more than one previous
systemic therapy. Patients with documented brain metastases
were not eligible. Informed consent was obtained from all
patients.
Human lymphoblastoid interferon (Wellferon) was
supplied by the Burroughs Welcome Company through
Pacific Isotopes and Pharmaceuticals of British Columbia.
The interferon preparation consists of a highly purified
mixture of alpha interferons (80-90%) extracted from the
supernatant of a suspension culture of Sendai virus - stimu-
lated lymphoblastoid cells derived from a Burkitt lymphoma
cell line (Namalwa).
The starting dose ofinterferon was 30Mum-2 and this was
escalated by 10Mum-2 each week to 100Mum-2 or until the
individual maximum tolerated dose (MTD) was achieved.
The appropriate dose of interferon was administered in
250ml of normal saline and infused i.v. over 3 h. Treatment
was to continue weekly for 6 months or until disease
progression. All patients received acetaminophen 650mg
every 4h beginning 2h before the interferon and for 12 to
24h following to reduce the febrile reaction. The MTD was
defined as that dose of interferon which could be adminis-
tered without unacceptable fever, chills and malaise and
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which was not associated with a fall in performance status of
more than one ECOG category. Doses were reduced by
10Mum-2 per treatment when the performance status fell by
more than one ECOG category over the baseline value or
when the interferon-induced fever, chills and malaise could
not be managed on an out-patient basis. Laboratory and
clinical evaluations for toxicity were carried out weekly.
Chest X-ray, CT scans and/or ultrasound examinations were
repeated every 4 weeks to follow sites of measurable disease.
Patients were considered to be evaluable for response after
4 weeks of therapy and evaluable for toxicity from the time
of entry onto the study. Standard criteria of response were
used: complete response was defined as disappearance of all
detectable disease for at least 4 weeks; partial response as a
minimum of 50% decrease in the sum of the products of the
two greatest perpendicular diameters of measurable disease
of at least 4 weeks duration with the appearance of no new
lesions; stable disease as less than 50% decrease or 25%
increase in tumour size lasting at least 8 weeks; progressive
disease as 25% or greater increase in tumour size and/or the
appearance of new lesions. Duration of response was defined
as the interval from the time response was first documented
until tumour progression occurred.
Forty-four patients entered the study between October
1983 and September 1984. Five were ineligible: 2 were found
to have pathology not consistent with renal cell carcinoma; 1
had no measurable disease; 1 had performance status ECOG
3; and 1 had renal insufficiency prior to starting interferon
therapy.
All 39 remaining patients were evaluable for toxicity and
37 were evaluable for response. Two were considered ineval-
uable for response: 1 went off study because of toxicity after
only 1 dose of interferon and the other had a presumed
pulmonary embolus and went off study after 2 doses of
interferon.
Patient characteristics are described in Table I. The
median age was 57 and thirty patients had an ECOG
performance status of 0 or 1. Twenty-seven patients were
previously untreated. The lung was the most common
metastatic site.
The median maximum tolerated dose was 60Mum- 2 per
week with a range from 30 to 100Mum-2. Patients received a
median of 8 weeks of therapy (range 1-26 weeks). As was
reported in the phase I study, the acute toxicity was a
symptom complex of fever, chills and malaise. Twenty-four
patients had a fall in performance status of one or two
ECOG levels. In some individuals this was clearly treatment
related, but in others it coincided with disease progression
and may have been multifactorial in origin. No hepatic
toxicity, myelosuppression, or renal toxicity was seen. One
patient developed an acute drug related thrombocytopenia
the day following his 18th dose of interferon. His platelet
count fell from 321,000mm-3 (pretreatment) to
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Table I Patient characteristics
Median Age (Range) 57 (37-73)
Sex
Male 32
Female 7
Performance statusa
ECOG 0 16
l 14
2 9
Prior therapy
None 27
Chemotherapy 7
Hormone therapy 5
Sites of disease
Lung 31 (major site in 22)
Kidney/retroperitoneum 16 (major site in 12)
Bone 14
Liver 7
aEastern Cooperative Oncology Group Criteria.
<0,000mm-3 within 24h and this was associated with the
development of a petechial rash and a buccal hematoma.
Subsequent investigation revealed high levels of platelet
associated IgG indicating that immune related platelet
destruction was the most likely mechanism for the thrombo-
cytopenia. The platelet count returned to normal within a
few days and the patient was taken off study. Eleven
patients demonstrated a transient, asymptomatic fall in
blood pressure at the time of treatment and 2 patients
developed dyspnea during the interferon infusion. A total of
3 patients were removed from the study because of toxicity
alone (one with thrombocytopenia, one with bronchospasm
and one with severe fatigue). A further 6 patients had both
toxicity and disease progression cited as the reasons for
going off study.
Response data are shown in Table II. Of the 37 patients
evaluable, 4 had documented partial responses. All responses
occurred after at least 12 weeks of therapy and at dose levels
from 70-100 Mum-2 of interferon. Seventeen of the 33
patients who did not achieve a response were escalated to these
doses of interferon. In two patients responses have been
Table II Tumour response (n =37)
Number Duration (weeks)
Complete response 0
Partial response 4 11, 13, 52+, 52+
Stable disease 16 median 12 (range 6-26)
Progressive disease 17
quite durable each lasting in excess of one year. The major
sites of disease in responders were lung in 3 cases and
retroperitoneum in one. Three of the 4 responding patients
were previously untreated and 3 had had a prior nephrectomy.
In this phase II study, a schedule of escalating weekly i.v.
interferon produced a response rate of 11% in a group of 37
patients with advanced renal cell carcinoma. The 95% upper
confidence limit of this observed response rate is 23%.
Other investigators utilizing different schedules of inter-
feron alpha have reported response rates in renal cell
carcinoma ranging from 7-26% (Quesada et al., 1983, 1985;
Neidhart et al., 1984; Kirkwood et al., 1985). Weekly
administration produced a comparable response rate and
was practical and acceptable to the majority of patients. The
primary toxicities were fever, chills, malaise and a fall in
performance status. Of note, and in keeping with the phase I
observations of Connors and Silver (1984), neither myelo-
suppression nor hepatotoxicity were seen. The rather low
response rates observed in this and other trials in which
alpha interferon has been used as a single agent in this
disease are disappointing and indicate there is little role for
the use of this drug alone in the management of advanced
renal cell carcinoma. Future studies with interferon will
undoubtedly focus upon its use in combination with other
cytotoxic drugs and we feel the attributes of the weekly
administration schedule in producing an altered spectrum of
toxicity should be considered when planning such trials.
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